Carmel Devlin

Learn More
BACKGROUND Streptococcus pneumoniae is a major cause of morbidity and mortality among adults 50 years of age and older in the United States. Pneumococcal conjugate vaccines are efficacious against pneumococcal disease in children and may also offer advantages in adults. METHODS We performed a randomized, modified double-blind trial that compared a single(More)
OBJECTIVES The efficacy and safety of 25-microg 17beta-estradiol vaginal tablets (Vagifem) were assessed and compared with 1.25-mg conjugated equine estrogen vaginal cream (Premarin Vaginal Cream) for the relief of menopausal-derived atrophic vaginitis, resulting from estrogen deficiency. DESIGN In a multicenter, open-label, randomized, parallel-group(More)
13-valent pneumococcal conjugate vaccine (PCV13) was compared to PCV7 in infants administered 4 doses. For the 7 common serotypes, PCV13- and PCV7-elicited responses showed comparable percent responders achieving 0.35mug/mL IgG threshold (exception 6B, 77.5% versus 87.1%, respectively) and OPA titers of 1:8; IgGs were lower than PCV7 but functional(More)
BACKGROUND The 13-valent pneumococcal conjugate vaccine (PCV13) has been demonstrated to be immunogenic and safe for administration to infants and children aged <5 years. PCV13 recently was approved for children and adolescents aged up to 17 years as the vaccine may be of benefit to some in this older age group. METHODS In this open-label study, healthy(More)
Paroxysmal atrial fibrillation was triggered by psychological stress in two patients, both of whom had normal echocardiograms and coronary angiography. Neither patient was alcoholic or had ingested ethanol in relation to the onset of atrial fibrillation and both were free of metabolic derangements. Possible mechanisms involved in the triggering of atrial(More)
Toxic side effects of elevated theophylline levels range from minor symptoms to life-threatening complications. We investigated the incidence of life-threatening events in patients with elevated levels in order to identify those at low risk for significant theophylline toxicity. Five hundred ten episodes of elevated levels were reviewed in 214 hospitalized(More)
BACKGROUND A 13-valent pneumococcal conjugate vaccine (PCV13) has been licensed in >100 countries to broaden coverage against pneumococcal disease. We assessed whether PCV13 interferes with immune responses to concomitantly administered routine pediatric vaccines. METHODS Healthy US infants were randomly assigned in 2 studies to receive PCV13 or 7-valent(More)
PReS-FINAL-2134: Assessment of radiographic progression in patients (pts) with systemic juvenile idiopathic arthritis (sjia) treated with tocilizumab (TCZ): 2-year results from the tender trial C Malattia, N Ruperto, E Palmisani, S Pederzoli, A Pistorio, HI Brunner, R Cuttica, I Calvo, SM Garay, D Eleftheriou, C Wouters, J Wang, C Devlin, D Lovell, A(More)
  • 1